Physician profile
Mark T Reding
NPI 1336223866
$518,786.40
in general payments reported to CMS, 2019-2025
17 companies · $70K in 2025
The $70K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $45K · 2021: $70K · 2022: $107K · 2023: $59K · 2024: $73K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $123K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Honoraria: $16K · Travel and Lodging: $11K · Food and Beverage: $3,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $122,580.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,338.61 |
| Honoraria | $15,500.00 |
| Travel and Lodging | $11,197.64 |
| Food and Beverage | $3,882.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $93,613.93 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $80,239.56 | 2019-2025 | |
| Novo Nordisk INC | $78,507.52 | 2019-2025 | |
| Csl Behring | $64,838.66 | 2019-2024 | Hemgenix, Idelvion |
| Takeda Pharmaceuticals U.S.A., INC. | $47,597.19 | 2020-2023 | Vonvendi |
| Hema Biologics, LLC | $37,124.26 | 2022-2025 | Sevenfact, Sevenfact |
| Genentech USA, INC. | $26,216.60 | 2022-2025 | Hemlibra |
| Shire North American Group INC | $22,939.56 | 2019 | |
| Biomarin Pharmaceutical INC. | $22,450.09 | 2021-2024 | Roctavian, Voxzogo 1.2mg |
| Sanofi US Services INC. | $19,805.00 | 2025 | |
| Bioverativ Therapeutics INC. | $7,710.00 | 2019-2021 | |
| Spark Therapeutics, INC. | $7,560.38 | 2022 | |
| Kedrion Biopharma, INC. | $4,200.00 | 2025 | Ryplazim |
| Sanofi-Aventis U.S. LLC | $3,559.50 | 2024 | |
| Pfizer INC. | $1,272.57 | 2020-2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,140.00 | 2025 | Hemlibra |
| Bio Products Laboratory USA, INC. | $11.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.